30
Participants
Start Date
December 24, 2018
Primary Completion Date
September 1, 2030
Study Completion Date
September 1, 2030
Follow up
the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
chemotherapy
First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
RECRUITING
Weiguo Lv, Hangzhou
Qilu Hospital of Shandong University
OTHER
Tongji Hospital Affiliated to Tongji Medical College of HUST
UNKNOWN
The First People's Hospital of Yunnan
OTHER
Tianjin Central Hospital of Gynecology Obstetrics
OTHER
Women and Children's Hospital of Ningbo University
UNKNOWN
First Affiliated Hospital of Wenzhou Medical University
OTHER
Hangzhou Fuyang Women And Children Hospital
UNKNOWN
Zhejiang Provincial Tongde Hospital
OTHER
Shaoxing Shangyu Women And Children Hospital
UNKNOWN
Huzhou Maternity and Child Health Care Hospital
UNKNOWN
Women's Hospital School Of Medicine Zhejiang University
OTHER